TLDR Vitiligo treatments are improving but relapses are common.
Vitiligo is a chronic autoimmune disorder affecting 0.5-2% of the global population, characterized by the destruction of melanocytes and resulting in depigmented skin patches. Its etiology involves genetic and environmental factors, oxidative stress, and immune response. Recent research explores the role of the skin and gut microbiome and neural factors in its pathogenesis. Treatment remains challenging, with current options like immunosuppressives, phototherapy, and JAK inhibitors providing only short-term benefits, as relapses are common after stopping treatment. New developments are focusing on targeted therapies, such as JAK inhibitors, to improve patient outcomes.
August 2024 in “Bioscience of Microbiota Food and Health” Microbes might play a role in vitiligo.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
18 citations
,
October 2022 in “Biomedicines” Regenerative treatments for vitiligo show promise but need more research for long-term safety and effectiveness.
14 citations
,
May 2019 in “Experimental Dermatology” Fat tissue extract may help treat vitiligo by reducing cell stress and promoting skin repair.
2 citations
,
January 2017 in “Journal of Pigmentary Disorders” Vitiligo causes white skin patches and can lead to psychological stress.
January 2025 in “Frontiers in Medicine” Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.
73 citations
,
January 2013 in “European journal of dermatology/EJD. European journal of dermatology” Antioxidants may help fight oxidative stress linked to autoimmune skin diseases.